GlassScriptPhysician profile
Lisa Henry Johnson
NPI 1861605214
$2,424.33
in general payments reported to CMS, 2019-2025
18 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $229 · 2023: $717 · 2024: $908 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $245.55 | 2024-2025 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $236.51 | 2023-2024 | Abilify Maintena, Abilify Asimtufii |
| Abbott Laboratories | $220.38 | 2023 | Freestyle Libre 3, Ensite Precision |
| Acadia Pharmaceuticals INC | $219.61 | 2024-2025 | Daybue |
| Silk Road Medical, INC. | $142.90 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Janssen Pharmaceuticals, INC | $137.86 | 2024 | Spravato |
| Sumitomo Pharma America, INC. | $124.99 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $124.36 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.84 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.95 | 2022 | |
| Abiomed | $119.91 | 2024 | Impella |
| Teva Pharmaceuticals USA, INC. | $114.14 | 2025 | Austedo Xr |
| Si-Bone, INC. | $109.52 | 2022 | |
| Edwards Lifesciences Corporation | $109.33 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| W. L. Gore & Associates, INC. | $91.99 | 2024 | Gore Viabahn Endoprosthesis With Heparin |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $88.53 | 2025 | Barostim Neo System |
| Pfizer INC. | $81.40 | 2024 | |
| Neurocrine Biosciences, INC. | $14.56 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Henry Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.